HAVCR2 and cancer: Based on the association of TIM-3 with T cell exhaustion in multiple settings [12, 15, 28], and its co-expression with PD-1, TIM-3 has emerged as a potential target worth investigating for development of an anti-cancer immunotherapy [29, 30] (reviewed in [31, 32]).